New drug combo aims to halt returning bone cancer

NCT ID NCT04417062

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. It includes 63 people aged 12 to 40. The goal is to see if the combination can stop the cancer from growing or delay its return.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA OSTEOSARCOMA RECURRENT

Contacts and locations

Locations

Dana Farber Cancer Institite

Boston, Massachusetts, 02115, United States
MD Anderson

Houston, Texas, 77030, United States
Memorial Sloan Kettering

New York, New York, 10065, United States
UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.